Amantadine hydrochloride is an antiviral agent that is also effective in the treatment of Parkinson's disease. In the literature, cardiac arrhythmia is reported in toxic doses of amantadine, but in this paper we report a patient with right ventricular outflow tract (RVOT) tachycardia after an initial dose of amantadine. A 47-year-old female patient was admitted to the emergency department with the complaint of palpitation and dizziness after taking 200 mg amantadine. A 12-lead standard ECG showed wide QRS complex tachycardia with a heart rate of 167/min. The wide QRS complex tachycardia had an inferior axis and left bundle branch block morphology, compatible with RVOT ventricular tachycardia (RVOT-VT). Tachycardia terminated spontaneously and sinus ECG was completely normal. No arrhythmia was inducible at the electrophysiological study. To the best of our knowledge, this is the first case in the literature to describe RVOT-VT after amantadine intake. Amantadine may cause RVOT-VT as well as other cardiac arrhythmias.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5543/tkda.2015.32885 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: RING finger protein 213 () p.R4810K is an established risk factor for moyamoya disease and intracranial artery stenosis in East Asian people. Recent evidence suggests its potential association with extracranial cardiovascular diseases, including pulmonary hypertension.
View Article and Find Full Text PDFLeft Main Coronary Occlusion During TAVI Procedure: Calcium Embolization Matters.
Catheter Cardiovasc Interv
January 2025
Department of Cardiac Anesthesia, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Acute coronary occlusion during transcatheter aortic valve implantation (TAVI) is an unwarranted complication associated with high mortality. The current TAVI practices recommend a multidetector computed tomography (MDCT) evaluation of the aortic valve, the left ventricular outflow tract, and the aortic root to determine the conventional risk factors for coronary obstruction like low-lying coronary ostia and narrow sinuses of Valsalva, mandating prophylactic coronary protection or native valve leaflet modification in high-risk patients. Despite optimal anatomy, acute coronary occlusion can still occur due to multiple mechanisms, one of which is coronary embolism due to thrombus, calcium, or native aortic valve fragments.
View Article and Find Full Text PDFRoadblock in left ventricular outflow tract: a rare intracardiac blood cyst.
Eur Heart J Cardiovasc Imaging
January 2025
Echocardiography Medical Center, Capital Medical University Affiliated Beijing Anzhen Hospital.
Right Ventricular Outflow Tract Obstruction: Transcatheter Correction In Tetralogy Of Fallot: A Pilot Study.
Am J Cardiol
January 2025
Department of Anaesthesiology, All India Institute of Medical Sciences, Kalyani, Kolkata.
This study evaluated transcatheter approach for relieving right ventricular outflow tract (RVOT) obstruction using combined non-compliant balloon dilatation of the RVOT and conal artery occlusion in patients with Tetralogy of Fallot (TOF), both uncorrected and post-intra-cardiac repair (ICR) restenosis. A prospective study was conducted from January 2022 to June 2023, including 40 symptomatic patients aged over 12 years with RVOT obstruction in TOF. Exclusion criteria included moderate to severe pulmonary regurgitation.
View Article and Find Full Text PDFThe Efficacy and Safety of Cardiac Myosin Inhibitors Versus Placebo in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
Am J Cardiol
January 2025
Department of Cardiovascular Medicine, Baystate Medical Center and Division of Cardiovascular Medicine, University of Massachusetts-Baystate, Springfield, Massachusetts, USA. Electronic address: https://twitter.com/AGoldsweig.
Introduction: Obstructive hypertrophic cardiomyopathy (oHCM) is a genetic disorder characterized by myocardial hypertrophy, which can obstruct left ventricular outflow. Cardiac myosin inhibitors (CMIs) have emerged as a novel therapeutic agent targeting cardiac muscle hypercontractility.
Objective: To compare the efficacy and safety of CMIs mavacamten and aficamten vs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!